title: Severe relapses under fingolimod treatment prescribed after natalizumab.
authors.affiliation: Multiple Sclerosis Clinical and Research Center, Department of Neuroscience, Tor Vergata University, Rome, Italy. centonze@uniroma2.it
authors.forename: Diego
authors.initials: D
authors.lastname: Centonze
authors.forename: Silvia
authors.initials: S
authors.lastname: Rossi
authors.forename: Francesca
authors.initials: F
authors.lastname: Rinaldi
authors.forename: Paolo
authors.initials: P
authors.lastname: Gallo
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D005260:Female; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007577:JC Virus / Q000276:immunology / Q000472:pathogenicity; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D000069442:Natalizumab; D011409:Propylene Glycols / Q000627:therapeutic use*; D012008:Recurrence; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine